The taxoids: paclitaxel (Taxol®) and docetaxel (Taxotere®)☆
作者： Richard Pazdur , Andrzej P. Kudelka , John J. Kavanagh , Philip R. Cohen , Martin N. Raber
DOI: 10.1016/0305-7372(93)90010-O
关键词:
摘要: The taxoids, paclitaxel (Taxol) and docetaxel (Taxotere), represent a novel class of antineoplastic drugs. Paclitaxel share similar mechanism action: the promotion microtubule assembly inhibition disassembly. clinical development was initially hampered by hypersensitivity reactions (HSRs). use premedications prolongation infusion time to 24h has reduced these allowed this drug's development. Although paclitaxel's activity not been fully investigated, trials have demonstrated its against ovarian, breast, bronchial carcinomas. Because phase I studies noted occasional HSRs observations increased with further experiences, those employed now instituted in many II docetaxel. Docetaxel is currently being investigated carcinomas shown impressive activity. dose-limiting toxicity both agents neutropenia; myalgias, mucositis, neuropathies, alopecia also observed Additionally, fluid retention syndrome cutaneous toxicities patients treated Future taxoids will allow comparisons efficacy agents.
elsevier.com
sci-hub.se 参考文章(73)
M. Christian, J. Adams, E. Reed, E. Rowinsky, M. Suffness, H. Strauss, W. McGuire, M. Oakes, H. Gibbs, S. G. Arbuck, A reassessment of cardiac toxicity associated with Taxol. Journal of The National Cancer Institute Monographs. pp. 117- 130 ,(1993)
D. C. Tormey, K. D. Tutsch, J. K. V. Willson, Santhanam Swaminathan, K. J. Simon, J. L. Grem, D. B. Alberti, D. L. Trump, Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer treatment reports. ,vol. 71, pp. 1179- 1184 ,(1987)
A. Setanoians, P. Wilson, M. A. Graham, V. Auzannet, G. A. Chadwick, D. J. Kerr, N. Le Bail, S. B. Kaye, D. Bissett, J. Cassidy, Phase I and Pharmacokinetic Study of Taxotere (RP 56976) Administered as a 24-Hour Infusion Cancer Research. ,vol. 53, pp. 523- 527 ,(1993)
David C. Allison, Ross C. Donehower, Eric K. Rowinsky, John R. Roberts, Development of polyploidization in taxol-resistant human leukemia cells in vitro. Cancer Research. ,vol. 50, pp. 710- 716 ,(1990)
David S. Ettinger, Philip J. Burke, Robert W. Tucker, Ross C. Donehower, Eric K. Rowinsky, Judith E. Karp, Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Research. ,vol. 49, pp. 4640- 4647 ,(1989)
E K Rowinsky, M R Gilbert, W P McGuire, D A Noe, L B Grochow, A A Forastiere, D S Ettinger, B G Lubejko, B Clark, S E Sartorius, Sequences of Taxol and Cisplatin: A Phase I and Pharmacologic Study Journal of Clinical Oncology. ,vol. 9, pp. 1692- 1703 ,(1991) , 10.1200/JCO.1991.9.9.1692
E. Boven, E. Venema-Gaberscek, C.A.M. Erkelens, M.C. Bissery, H.M. Pinedo, Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer Annals of Oncology. ,vol. 4, pp. 321- 324 ,(1993) , 10.1093/OXFORDJOURNALS.ANNONC.A058491
D M Peereboom, R C Donehower, E A Eisenhauer, W P McGuire, N Onetto, J L Hubbard, M Piccart, L Gianni, E K Rowinsky, Successful re-treatment with taxol after major hypersensitivity reactions. Journal of Clinical Oncology. ,vol. 11, pp. 885- 890 ,(1993) , 10.1200/JCO.1993.11.5.885
Françoise Guéritte-Voegelein, François Lavelle, Daniel Guénard, Marie-Christine Bissery, Experimental Antitumor Activity of Taxotere (RP 56976, NSC 628503), a Taxol Analogue Cancer Research. ,vol. 51, pp. 4845- 4852 ,(1991)
Renzo M. Canetta, Renzo M. Canetta, Eric K. Rowinsky, Eric K. Rowinsky, Susan G. Arbuck, Susan G. Arbuck, Nicole Onetto, Nicole Onetto, Taxol: the first of the taxanes, an important new class of antitumor agents. Seminars in Oncology. ,vol. 19, pp. 646- 662 ,(1992) , 10.5555/URI:PII:009377549290034X